Cardio Diagnostics Holdings (NASDAQ: CDIO) is leveraging artificial intelligence, epigenetics, and genetics to improve the early detection and diagnosis of coronary heart disease through its blood-based Epi+Gen CHD and PrecisionCHD tests. The company addresses a cardiovascular disease market projected to grow from $393 billion in annual healthcare costs in 2020 to $1.4 trillion by 2050.
Cardio Diagnostics’ proprietary AI-driven Multi-Omics Engine analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including certain nonobstructive forms that conventional diagnostic methods may miss. This positions the company at the forefront of precision medicine, where AI is increasingly used to unlock insights from complex biological data.
The company has strengthened its commercialization efforts through securing finalized CMS reimbursement rates and dedicated CPT laboratory codes. These milestones are critical for widespread adoption, as they ensure healthcare providers can be reimbursed for offering the tests. Additionally, Cardio Diagnostics is expanding U.S. provider partnerships and has launched its first international expansion in India, signaling growing global demand for advanced cardiovascular diagnostics.
With a proprietary AI-driven platform, reimbursement milestones, growing provider adoption, and evidence supporting the ability to detect what traditional tools miss, Cardio Diagnostics occupies a position that is both scientifically grounded and commercially actionable in the diagnostics landscape. The company’s progress underscores the broader trend of AI integration into healthcare, where data-driven approaches are enabling earlier and more accurate disease detection.
For more information, visit the company’s newsroom at https://nnw.fm/CDIO.
